Considering the challenges of conducting head-to-head clinical trials, indirect treatment comparisons (ITCs) offer valuable insights into clinical effectiveness that reflect current and local practices. These insights can help regulators and reimbursement agencies make better-informed decisions, thereby facilitating patient access to novel treatments. Recent methodological advancements in ITCs have led to the release of regional, national and global guidelines outlining jurisdiction-specific methodology and reporting recommendations and/or best practices.
The Value & Evidence team at EVERSANA (Krista Tantakoun, Christopher Olsen, Fatemeh Mirzayeh Fashami, Imtiaz Samjoo and Chris Cameron), in collaboration with Dr. Brian Hutton, professors at Kyoto University and Yokohama City University School of Medicine in Japan, and colleagues at Janssen Pharmaceutical, critically reviewed and synthesized ITC guidelines around the world, including those of various international organizations, regulatory bodies and health technology assessment agencies. This comprehensive literature review highlights key ITC techniques for objective and analytically sound analyses and ascertains the circumstantial suitability of ITCs as a source of comparative evidence for healthcare interventions.
This work underscores the importance of ITCs in the absence of head-to-head clinical trials, emphasizes the need for up-to-date and standardized guidance, and highlights the role of ITCs in recognizing the value of innovative treatments across different jurisdictions.
For a deeper understanding, access the Value in Health article: https://pubmed.ncbi.nlm.nih.gov/38843980/.
Author
As an Associate Manager on the Value & Evidence team at EVERSANA™, Krista contributes to evidence synthesis projects that support global HEOR initiatives. Since joining the team in 2020, Krista has been involved in…
Christopher is a Research Assistant II in the Evidence Synthesis group at EVERSANA. Christopher has been with EVERSANA since 2021 where he has supported systematic and targeted literature reviews across a variety of disease areas including prostate…
Fatemeh is a Research Associate in the Value & Evidence Division at EVERSANA, with experience in evidence synthesis, value communications, and economic modelling. Fatemeh holds an MSc in Health Research Methodology in the HTA…
As Senior Director of the Value & Evidence team at EVERSANA, Imtiaz leads evidence synthesis projects that support global HEOR initiatives involving systematic literature reviews, indirect treatment comparisons, and health economic modeling, to support reimbursement…
Dr. Chris Cameron is a global thought leader in health economics and outcomes research with over a decade of experience. Prior to joining EVERSANA, Chris was a partner at Cornerstone Research Group Inc., and…